Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and Roto-Rooter.</li><li>The company reports strong performance from VITAS, while Roto-Rooter is facing challenges.</li><li>VITAS Healthcare displayed robust growth in the quarter, primarily driven by increased admissions and the successful acquisition of Covenant Health.</li></ul>

Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and Roto-Rooter.The company reports strong performance from VITAS, while Roto-Rooter is facing challenges.VITAS Healthcare displayed robust growth in the quarter, primarily driven by increased admissions and the successful acquisition of Covenant Health.

Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers

<ul><li>Chemed Corporation, a diversified company primarily engaged through its subsidiaries, VITAS Healthcare Corporation and Roto-Rooter, recently provided updates in their Second Quarter 2024 Earnings Call.</li><li>The overview pulls into focus a mixed performance within its distinct operations.</li><li>Starting with VITAS Healthcare Corporation, there's a pronounced positive trajectory witnessed in the segment, particularly off the back of the acquisition of Covenant Health.</li></ul>

Chemed Corporation, a diversified company primarily engaged through its subsidiaries, VITAS Healthcare Corporation and Roto-Rooter, recently provided updates in their Second Quarter 2024 Earnings Call.The overview pulls into focus a mixed performance within its distinct operations.Starting with VITAS Healthcare Corporation, there's a pronounced positive trajectory witnessed in the segment, particularly off the back of the acquisition of Covenant Health.

Chemed Corporation: Integration of Covenant Health

<ul><li>Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024.</li><li>The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter.</li><li>VITAS, Chemed's healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year.</li></ul>

Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024.The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter.VITAS, Chemed's healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year.

Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! - Major Drivers

<ul><li>Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7% increase in admissions over the prior year period and an average daily census of 1,918.</li><li>This is an 11% increase in comparison to the prior year and suggests that a hiring and retention program initiated in 2022 to remedy any potential worker turnover and expand clinical workforce capacity has been successful in maintaining VITAS' operational performance.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7% increase in admissions over the prior year period and an average daily census of 1,918.This is an 11% increase in comparison to the prior year and suggests that a hiring and retention program initiated in 2022 to remedy any potential worker turnover and expand clinical workforce capacity has been successful in maintaining VITAS' operational performance.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage - Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Select Medical Holdings / Technical Analysis

<ul>
<li>We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.</li>
<li>We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.</li>
<li>Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.</li>
</ul>


We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.
We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.
Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.


Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

United States

Chemed Corporation operates in the healthcare field through its subsidiary Vitas Healthcare Corporation.  The Company also maintains a presence in the residential and commercial repair-and-maintenance-service industry under the names Roto-Rooter and Service America Network Inc.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chemed Corp (CHE US)

Chemed Corporation: How Is The Management Tackling Roto-Rooter Challenges & Other Risks? -Major Drivers

Chemed Corporation's third-quarter 2024 earnings present a mixed performance across its two primary business segments: VITAS Healthcare and...

Baptista Research

Chemed Corporation: Integration of Covenant Health

Chemed Corporation, a diversified company primarily engaged through its subsidiaries, VITAS Healthcare Corporation and Roto-Rooter, recently...

Baptista Research

Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! - Major Drivers

Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024. The earnings showed...

Baptista Research

Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage - Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! - Major Drivers

Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7%...

Baptista Research

Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

Positive developments are popping up, such as bullish reversals of 4-5-month downtrends for Financials $XLF and Broker-Dealers/Exchanges $IAI ....

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)